http://www.gosreports.com
Chronic Urticaria Or Hives – Pipeline Review by Gosreports 2021
Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin’s surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Full Report:
http://www.gosreports.com/global-diammonium-hydrogen-phosphate-dap-market-research-report-2016/
The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 2 and 3 respectively for Chronic Urticaria Or Hives.
Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Table of contents:
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Urticaria Or Hives Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Urticaria Or Hives – Overview 8
Chronic Urticaria Or Hives – Therapeutics under Development by Companies 9
Chronic Urticaria Or Hives – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Chronic Urticaria Or Hives – Products under Development by Companies 13
Chronic Urticaria Or Hives – Companies Involved in Therapeutics Development 14
Biofrontera AG 14
ELORAC, Inc. 15
F. Hoffmann-La Roche Ltd. 16
Genentech, Inc. 17
GlaxoSmithKline Plc 18
Mabtech Limited 19
Mycenax Biotech Inc. 20
Novartis AG 21
Panacea Biotec Limited 22
Synermore Biologics Co Ltd 23
Chronic Urticaria Or Hives – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
BF-Derm-1 – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
cidoxepin hydrochloride – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GSK-2646264 – Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
JDP-205 – Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ligelizumab – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
omalizumab – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
omalizumab biosimilar – Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
omalizumab biosimilar – Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
omalizumab biosimilar – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
omalizumab biosimilar – Drug Profile 47
Product Description 47
Mechanism Of Action 47
……………………
More Information:
http://www.gosreports.com/global-ozokerite-wax-market-research-report-2016/
http://www.gosreports.com/global-diammonium-hydrogen-phosphate-dap-market-research-report-2016/
Contacts Us
Joanna | Executive - International Business and partner Relations
E-mail: [email protected] 
Tel: 001-510-400-8520
Web: www.gosreports.com